Parkinson's Disease (Adult)

1. Clinical Overview

Summary

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta, resulting in striatal dopamine deficiency and the characteristic motor syndrome. [1,2] It is the second most common neurodegenerative disease after Alzheimer's disease, affecting over 6 million people worldwide with prevalence expected to double by 2040 due to population aging. [3]

The cardinal motor features comprise bradykinesia (mandatory for diagnosis), resting tremor, rigidity, and postural instability (the latter typically emerging in later disease stages). However, PD is now recognized as a multisystem alpha-synucleinopathy with extensive non-motor manifestations—including autonomic dysfunction, cognitive impairment, neuropsychiatric symptoms, sleep disorders, and sensory abnormalities—that often precede motor symptoms by 10-20 years during the "prodromal phase." [2,4]

The diagnosis remains fundamentally clinical, based on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria, which require the presence of parkinsonism (bradykinesia plus tremor or rigidity), the absence of exclusion criteria, and the presence of supportive criteria. [5] Management is primarily symptomatic, centering on dopamine replacement therapy with levodopa (the most effective agent), dopamine agonists, and MAO-B inhibitors. While no disease-modifying therapy currently exists, substantial research is ongoing. Advanced therapies including deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG), and subcutaneous apomorphine infusion provide significant benefit for patients with motor complications refractory to optimized oral therapy. [6,7]

Key Facts

Clinical Pearls

"Bradykinesia is the sine qua non of Parkinson's" — You cannot diagnose PD without bradykinesia, which must include slowness of movement AND progressive decrement in speed or amplitude during repetitive movements. A patient with tremor alone does not have Parkinson's disease.

"The 4-6 Hz pill-rolling tremor" — The classic PD tremor is a 4-6 Hz resting tremor that characteristically decreases or disappears during voluntary movement and during sleep. It is typically asymmetric and may have a re-emergent component when the posture is maintained.

"Watch the eyes and the gait for Parkinson-Plus" — Early falls (within the first year) or supranuclear vertical gaze palsy should immediately raise suspicion for Progressive Supranuclear Palsy. Early autonomic failure suggests Multiple System Atrophy.

"Non-motor symptoms often matter more to patients" — While clinicians focus on the motor syndrome, patients frequently report that depression, cognitive impairment, sleep fragmentation, fatigue, and autonomic dysfunction are more disabling than the motor symptoms.

"The honeymoon period typically lasts 3-5 years" — Most patients experience excellent symptom control with levodopa initially, but motor complications (fluctuations and dyskinesias) eventually develop in the majority. After 10 years, up to 90% will experience motor fluctuations. [8]

"Time matters for DBS" — The EARLYSTIM trial demonstrated that DBS is most beneficial when offered early in the course of motor complications, not as a therapy of last resort. [7]

Why This Matters Clinically

Parkinson's disease is a major cause of disability in the aging population, with profound impacts on quality of life, caregiver burden, and healthcare costs. Early and accurate diagnosis is crucial for:

1. Initiating appropriate symptomatic treatment to maintain function and quality of life
2. Providing accurate prognosis — distinguishing idiopathic PD (relatively good prognosis) from "Parkinson-plus" syndromes (poor prognosis)
3. Avoiding harm — drug-induced parkinsonism from dopamine blockers requires cessation, not dopaminergic treatment
4. Planning for the future — discussing driving, work capacity, advance care planning
5. Timely referral for advanced therapies — recognizing the "levodopa-induced complications" phase for DBS or pump therapies
6. Managing the whole patient — addressing the full spectrum of motor and non-motor symptoms

As the "Parkinson's pandemic" unfolds with projected doubling of cases by 2040, competence in PD diagnosis and management is essential for all physicians. [3]

---

2. Epidemiology

Incidence and Prevalence

Parkinson's disease demonstrates a strong age-dependent distribution, with incidence and prevalence rising exponentially after age 60. [1,9]

Global Burden: The Global Burden of Disease study documented 6.2 million individuals with PD worldwide in 2015, representing a 118% increase since 1990. This is the fastest-growing neurological disorder. [3]

Age of Onset:

• Late-onset PD: > 60 years (most common)
• Early-onset PD: 40-60 years
• Young-onset PD (YOPD): less than 40 years (~5% of cases; higher genetic contribution)
• Juvenile-onset PD: less than 21 years (rare; almost always genetic)

Demographics

Genetic Architecture of Parkinson's Disease

Understanding the genetic landscape is increasingly relevant for counseling and emerging therapies. [10]

Autosomal Dominant Genes

Autosomal Recessive Genes

Major Susceptibility Gene

Risk Factors

Non-Modifiable Risk Factors:

• Age (primary risk factor)
• Male sex
• Family history (especially in YOPD)
• Specific genetic variants (GBA, LRRK2, SNCA, PRKN)

Modifiable/Environmental Risk Factors:

Differential Diagnosis of Parkinsonism

Approximately 15-25% of patients initially diagnosed with PD are ultimately found to have an alternative diagnosis. [4]

---

3. Pathophysiology

The Alpha-Synuclein Hypothesis

The central pathogenic event in Parkinson's disease is the misfolding and aggregation of alpha-synuclein (α-synuclein), a 140-amino acid protein normally found at presynaptic terminals, into insoluble fibrillar inclusions. [1,2]

Alpha-Synuclein Structure and Function

• Normal function: Involved in synaptic vesicle trafficking, neurotransmitter release, and synaptic plasticity
• Structure: Natively unfolded protein that adopts α-helical conformation when bound to membranes
• Aggregation cascade:
  1. Monomers → Oligomers (most toxic species) → Protofibrils → Mature fibrils
  2. Fibrils deposit as Lewy bodies (cytoplasmic) and Lewy neurites (in axons and dendrites)
  3. Oligomers impair mitochondrial function, proteasomal degradation, and membrane integrity

The Braak Hypothesis: Prion-like Propagation

Braak and colleagues proposed that α-synuclein pathology originates in peripheral sites and spreads centripetally to the brain via the vagus nerve. [12]

BRAAK STAGING OF PARKINSON'S DISEASE PATHOLOGY

Stage 1-2: PERIPHERAL/LOWER BRAINSTEM (PRODROMAL)
├── Olfactory bulb → Anosmia
├── Enteric nervous system → Constipation
├── Dorsal motor nucleus of vagus → Autonomic dysfunction
└── Lower brainstem → REM sleep behavior disorder

              ↓ Rostral progression via connected neurons

Stage 3-4: MIDBRAIN (MOTOR PHASE)
├── Substantia nigra pars compacta → Cardinal motor features
├── Locus coeruleus → Depression, attention deficits
├── Raphe nuclei → Sleep disorders, mood disturbance
└── Pedunculopontine nucleus → Gait and balance dysfunction

              ↓ Continued spread to higher structures

Stage 5-6: CORTICAL (ADVANCED)
├── Limbic structures → Neuropsychiatric symptoms
├── Neocortex → Cognitive impairment, dementia
└── Hippocampus → Memory dysfunction

Evidence for prion-like spread:

• Post-mortem studies of fetal dopamine neuron transplant recipients showed development of Lewy bodies in grafted neurons after 10-16 years
• α-synuclein fibrils can seed aggregation when injected into animal brains
• Truncal vagotomy associated with reduced PD risk

Substantia Nigra Degeneration

The substantia nigra pars compacta (SNpc) contains approximately 400,000-600,000 dopaminergic neurons in the healthy brain. [1,2]

Why SNpc Neurons Are Selectively Vulnerable

Threshold for Symptom Onset

• Motor symptoms emerge when 50-60% of SNpc dopaminergic neurons are lost
• This corresponds to 70-80% depletion of striatal dopamine
• Compensatory mechanisms (increased dopamine turnover, receptor upregulation) maintain function initially
• Putamen is affected earlier and more severely than caudate

Mitochondrial Dysfunction and Oxidative Stress

Mitochondrial complex I deficiency is a consistent finding in PD. [2]

MITOCHONDRIAL DYSFUNCTION CASCADE

Environmental toxins (Rotenone, MPTP, Paraquat)
                    ↓
        Inhibit Complex I of electron transport chain
                    ↓
        ↓ ATP production + ↑ Reactive Oxygen Species (ROS)
                    ↓
┌───────────────────┼───────────────────┐
↓                   ↓                   ↓
Lipid peroxidation  Protein oxidation   DNA damage
↓                   ↓                   ↓
Membrane damage     Protein aggregation  Apoptosis signals
                    (α-synuclein)
                    ↓
              NEURONAL DEATH

Key genetic evidence linking mitochondria to PD:

• PINK1 and Parkin (recessive PD genes) function in mitophagy (clearance of damaged mitochondria)
• DJ-1 is a mitochondrial antioxidant
• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes parkinsonism by inhibiting complex I

Basal Ganglia Circuitry: Direct and Indirect Pathways

Understanding basal ganglia physiology is essential for understanding PD symptoms and the mechanism of DBS. [1,2]

NORMAL BASAL GANGLIA FUNCTION

                    CORTEX
                      │
                      ↓ Glutamate (+)
                   STRIATUM
                   /       \
        D1 (direct)         D2 (indirect)
              ↓                   ↓
            GPi/SNr ←──────── GPe
              │                   │
              ↓                   ↓
           THALAMUS            STN
              │                   │
              ↓                   ↓
            CORTEX ←──────────────┘

DIRECT PATHWAY: Facilitates movement (D1 receptors)
Striatum ─(GABA)→ GPi/SNr ─(GABA)→ Thalamus → Cortex
Net effect: Disinhibition of thalamus → MOVEMENT

INDIRECT PATHWAY: Inhibits movement (D2 receptors)
Striatum ─(GABA)→ GPe ─(GABA)→ STN ─(Glutamate)→ GPi/SNr
Net effect: Increased inhibition of thalamus → NO MOVEMENT

Dopamine Depletion Effects

Non-Dopaminergic Neurodegeneration

PD involves multiple neurotransmitter systems beyond dopamine, explaining the diverse non-motor symptoms. [2]

---

4. Clinical Presentation

Motor Symptoms: The Cardinal Features

The diagnosis of Parkinson's disease requires the presence of parkinsonism, defined as bradykinesia plus at least one of resting tremor or rigidity. [5]

1. Bradykinesia (Required for Diagnosis)

Bradykinesia is the defining motor feature and is mandatory for diagnosis. [5]

Definition: Slowness of movement initiation with progressive reduction in speed AND amplitude during repetitive movements (the "decremental" feature is pathognomonic).

Clinical Manifestations of Bradykinesia:

• Hypomimia ("masked facies"): Reduced facial expression and blink rate
• Hypophonia: Soft, monotonous voice
• Micrographia: Handwriting becomes progressively smaller
• Reduced arm swing: Usually unilateral initially
• Difficulty with fine motor tasks: Buttoning, using utensils
• Prolonged movement times: Everything takes longer

2. Resting Tremor

Present in 70-75% of patients at diagnosis; some never develop tremor ("akinetic-rigid" phenotype). [1,2]

Differentiating PD Tremor from Essential Tremor:

3. Rigidity

Increased resistance to passive movement, independent of velocity. [1,2]

Distribution: Usually begins unilaterally, affecting neck and proximal limbs; axial rigidity becomes prominent later.

Differentiation from Spasticity:

4. Postural Instability

Usually a late feature; early postural instability suggests alternative diagnosis. [5]

• Pull test: Examiner stands behind patient and pulls shoulders backward; > 2 steps to recover or need for catching is abnormal
• Falls: Leading cause of morbidity in advanced PD
• Festination: Progressive acceleration of gait with shortening steps (trying to catch up with center of gravity)
• Freezing of gait (FOG): Sudden, transient inability to initiate or continue walking; often triggered by doorways, turns, or narrow spaces

Motor Phenotypes

Patients can be categorized into motor phenotypes with prognostic implications. [2,4]

Non-Motor Symptoms

Non-motor symptoms (NMS) affect virtually all PD patients and often cause greater disability than motor symptoms. [4,13]

Autonomic Dysfunction

Neuropsychiatric Manifestations

Sleep Disorders

Sensory and Pain Syndromes

Prodromal Parkinson's Disease

Increasing recognition of the prodromal (pre-motor) phase has major implications for early identification and future neuroprotective trials. [4]

TIMELINE OF SYMPTOM EMERGENCE

20-10 years before motor onset:
├── Constipation
├── Depression/Anxiety
└── Anosmia/Hyposmia

10-5 years before motor onset:
├── REM sleep behavior disorder
├── Subtle cognitive changes
├── Seborrhea
└── Excessive daytime sleepiness

5-0 years before motor onset:
├── Subtle motor signs (reduced arm swing)
├── Urinary symptoms
├── Erectile dysfunction
└── Orthostatic hypotension

Motor onset:
├── Bradykinesia + tremor/rigidity
└── Asymmetric presentation

MDS Prodromal PD Criteria: Combine risk/protective factors (age, sex, family history, smoking, caffeine) with prodromal markers (RBD, hyposmia, constipation, depression, subtle motor signs, DaTscan) to calculate probability of prodromal PD.

Red Flags for Atypical Parkinsonism

[!CAUTION] Red Flags — Consider Atypical Parkinsonism (Parkinson-Plus):

• Rapid progression — Wheelchair dependence within 5 years
• Early falls — Within the first year of symptom onset (suggests PSP)
• Early severe autonomic failure — Symptomatic orthostatic hypotension or urinary incontinence (suggests MSA)
• Supranuclear vertical gaze palsy — Particularly downgaze limitation (pathognomonic for PSP)
• Poor or absent response to levodopa — Even at adequate doses (≥1000mg/day for ≥1 month)
• Symmetric onset — Idiopathic PD is almost always asymmetric at onset
• Early dementia — Cognitive decline within 1 year of motor onset (suggests DLB; use "1-year rule")
• Cerebellar signs — Ataxia, scanning speech, nystagmus (suggests MSA-C)
• Prominent pyramidal signs — Spasticity, hyperreflexia, Babinski (suggests atypical parkinsonism)
• Inspiratory stridor — Laryngeal dystonia (suggests MSA)
• Alien limb phenomenon — Limb acts independently of patient's will (suggests CBS)
• Disproportionate antecollis — Severe neck flexion (suggests MSA)

---

5. Clinical Examination

Systematic Neurological Examination for Parkinsonism

1. General Observation

2. Tremor Assessment

3. Rigidity Assessment

4. Bradykinesia Testing (MDS-UPDRS Items)

5. Gait and Balance Assessment

6. Additional Signs

7. Eye Movement Examination (Critical for Parkinson-Plus)

Specific Named Signs

---

6. Investigations

Clinical Diagnosis

Parkinson's disease remains a clinical diagnosis. There is no definitive diagnostic test.

The MDS Clinical Diagnostic Criteria for PD (2015) provide a standardized approach. [5]

MDS Clinical Diagnostic Criteria

Step 1: Establish Parkinsonism

• Bradykinesia (mandatory) PLUS
• Resting tremor and/or rigidity

Step 2: Apply Exclusion Criteria (Absolute; if present, PD is excluded)

• Cerebellar abnormalities
• Supranuclear downgaze palsy or selective slowing of downward saccades
• Probable behavioral variant frontotemporal dementia or primary progressive aphasia within first 5 years
• Parkinsonism restricted to lower limbs for > 3 years
• Treatment with dopamine receptor blockers or dopamine-depleting agents in a dose/time consistent with drug-induced parkinsonism
• Absence of observable response to high-dose levodopa despite at least moderate disease severity
• Unequivocal cortical sensory loss, clear limb ideomotor apraxia, or progressive aphasia
• Normal functional neuroimaging of presynaptic dopaminergic system (DaTscan)
• Documentation of alternative condition known to produce parkinsonism

Step 3: Count Supportive Criteria

• Clear and dramatic beneficial response to dopaminergic therapy
• Presence of levodopa-induced dyskinesia
• Rest tremor of a limb
• Olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy

Step 4: Apply Red Flags (each red flag must be counterbalanced by a supportive criterion)

Diagnostic Certainty:

• Clinically Established PD: No absolute exclusion criteria, ≥2 supportive criteria, no red flags
• Clinically Probable PD: No absolute exclusion criteria, red flags counterbalanced by supportive criteria

Neuroimaging

1. Structural MRI Brain

Advanced MRI techniques (research/specialized centers):

• SWI/Neuromelanin imaging: Loss of "swallow tail sign" in SNpc
• Diffusion tensor imaging: White matter tract changes

2. DaTscan (Ioflupane I-123 SPECT)

Assesses presynaptic dopamine transporter (DAT) density in the striatum. [14]

3. Cardiac MIBG Scintigraphy

Laboratory Investigations

Routine labs are not diagnostic but help exclude secondary causes:

Genetic Testing

Consider in:

• Young-onset PD (less than 40-50 years)
• Strong family history
• Specific populations (Ashkenazi Jewish, North African Arab for LRRK2)
• Research or clinical trial eligibility

Additional Testing Based on Clinical Picture

---

7. Management

Principles of Management

Management of PD is symptomatic (no disease-modifying therapy is proven). Goals include:

1. Maintain independence and quality of life
2. Treat motor symptoms to acceptable patient-defined targets
3. Recognize and manage non-motor symptoms
4. Minimize treatment complications
5. Plan for advanced disease
6. Engage multidisciplinary team early

Treatment Initiation

When to start treatment: Treatment should begin when symptoms cause functional impairment or distress to the patient. There is no evidence that delaying treatment provides any protective benefit. [6,15]

INITIAL THERAPY DECISION ALGORITHM

                    PATIENT WITH NEWLY DIAGNOSED PD
                    (Bradykinesia + Tremor/Rigidity)
                              │
                              ▼
              ┌───────────────────────────────┐
              │  Are symptoms affecting       │
              │  quality of life or function? │
              └───────────────────────────────┘
                   │                    │
                  YES                   NO
                   │                    │
                   ▼                    ▼
        ┌─────────────────┐    ┌─────────────────┐
        │  Initiate       │    │  Monitor;       │
        │  Pharmacotherapy │    │  Lifestyle      │
        │                 │    │  modifications  │
        └─────────────────┘    │  (exercise)     │
                   │           └─────────────────┘
                   ▼
    ┌─────────────────────────────────────────────┐
    │     CONSIDER PATIENT FACTORS:               │
    │  • Age                                      │
    │  • Severity of symptoms                     │
    │  • Employment/activity demands              │
    │  • Cognitive status                         │
    │  • Patient preference                       │
    └─────────────────────────────────────────────┘
                   │
        ┌──────────┼──────────┐
        │          │          │
        ▼          ▼          ▼
   ┌────────┐ ┌────────┐ ┌────────┐
   │ YOUNG  │ │ OLDER  │ │ MILD   │
   │ (less than 60y) │ │ (> 70y) │ │ SYMPTS │
   │ Active │ │ Cog.   │ │ Any    │
   │ concern│ │ risk   │ │ age    │
   │ for    │ │        │ │        │
   │ dyski- │ │        │ │        │
   │ nesias │ │        │ │        │
   └────────┘ └────────┘ └────────┘
        │          │          │
        ▼          ▼          ▼
   ┌────────┐ ┌────────┐ ┌────────┐
   │Dopamine│ │LEVODOPA│ │MAO-B   │
   │Agonist │ │(first- │ │Inhibitor│
   │or      │ │line if │ │        │
   │MAO-B-I │ │QoL     │ │Rasagi- │
   │        │ │impact) │ │line    │
   └────────┘ └────────┘ └────────┘

Pharmacotherapy

1. Levodopa: The Gold Standard

Levodopa remains the most effective medication for motor symptoms of PD. [6,15]

Adverse Effects:

2. Dopamine Agonists

Directly stimulate dopamine receptors (D2/D3). [6,15]

Indications:

• Early monotherapy in younger patients (less than 60-65) to delay levodopa complications
• Adjunct to levodopa for motor fluctuations
• Apomorphine for refractory "off" periods

Adverse Effects:

[!CAUTION] Impulse Control Disorders — Dopamine agonists carry significant risk of ICDs. Screen all patients before starting and at each visit. Ask directly about gambling, excessive spending, hypersexuality, binge eating, and punding.

3. MAO-B Inhibitors

Inhibit monoamine oxidase type B, the enzyme that metabolizes dopamine in the brain. [6,15]

Indications:

• Mild symptoms (can use as monotherapy)
• Adjunct to levodopa (extends duration, reduces "off" time)

Adverse Effects:

• Generally well tolerated
• Insomnia (selegiline > rasagiline)
• Headache
• Serotonin syndrome: Theoretical risk with SSRIs/SNRIs, though clinically rare at MAO-B selective doses
• Tyramine reaction: Very rare with MAO-B selective doses (dietary restriction unnecessary)

4. COMT Inhibitors

Block catechol-O-methyltransferase, reducing peripheral levodopa metabolism. [6,15]

Indications:

• Wearing-off fluctuations (extends levodopa duration by 30-60 minutes per dose)

Adverse Effects:

• Dyskinesias (due to increased levodopa exposure — may need to reduce levodopa dose)
• Orange/brown discoloration of urine
• Diarrhea (common with entacapone; may be delayed onset)
• Hepatotoxicity (tolcapone — LFT monitoring required)

5. Amantadine

Originally an antiviral; mechanism in PD is complex (weak NMDA antagonist, dopamine release). [6]

Formulations:

• Immediate-release (100mg BID-TID)
• Extended-release (Gocovri, Osmolex): Specifically approved for dyskinesias; given at bedtime

Adverse Effects:

• Livedo reticularis (reticular purple discoloration of skin)
• Peripheral edema
• Hallucinations, confusion (especially in elderly — avoid if cognitive impairment)
• Anticholinergic effects
• Insomnia

6. Anticholinergics

Block muscarinic acetylcholine receptors; used for tremor. [6]

Indications: Tremor-dominant PD in young patients only

Adverse Effects: Cognitive impairment, confusion, hallucinations, urinary retention, constipation, dry mouth, blurred vision

[!CAUTION] Avoid anticholinergics in elderly patients — High risk of confusion, cognitive worsening, urinary retention, and falls. Use is limited to young, cognitively intact patients with tremor-dominant disease.

Motor Fluctuations and Dyskinesias

Motor complications develop in 40-50% of patients within 5 years of levodopa initiation and in up to 90% after 10 years. [8]

Types of Motor Fluctuations

Dyskinesias

Management of Motor Fluctuations

WEARING-OFF MANAGEMENT ALGORITHM

Step 1: OPTIMIZE LEVODOPA
├── More frequent doses (smaller, more often)
├── Avoid taking with protein-rich meals
└── Consider controlled-release preparations

Step 2: ADD ADJUNCT THERAPY
├── COMT inhibitor (entacapone/opicapone)
│   → Extends levodopa duration by 30-60 min
├── MAO-B inhibitor (rasagiline/safinamide)
│   → Reduces "off" time by ~1 hour/day
└── Dopamine agonist
    → Longer half-life provides smoother effect

Step 3: ADDRESS DYSKINESIAS (if present)
├── Amantadine (especially extended-release)
├── Reduce levodopa dose (may worsen parkinsonism)
└── Consider advanced therapies

Step 4: CONSIDER ADVANCED THERAPIES
├── Deep brain stimulation
├── Levodopa-carbidopa intestinal gel (LCIG)
└── Subcutaneous apomorphine infusion

Advanced Therapies

For patients with motor fluctuations refractory to optimized oral therapy. [7]

Deep Brain Stimulation (DBS)

DBS is the most established advanced therapy for PD. [7]

Mechanism: High-frequency stimulation (typically 130-180 Hz) of deep brain structures disrupts pathological oscillatory activity and reduces output from the GPi or modulates STN function.

Targets:

• Subthalamic nucleus (STN): Most common; allows reduction in medication
• Globus pallidus interna (GPi): Preferred if significant dyskinesias; cognitive concerns
• Ventral intermediate nucleus of thalamus (VIM): Tremor only (rarely used in PD)

Indications:

• Motor fluctuations and dyskinesias not adequately controlled with optimized medical therapy
• Good response to levodopa (predicts DBS success)
• Disabling tremor unresponsive to medication

Contraindications:

• Significant cognitive impairment or dementia
• Uncontrolled psychiatric illness
• Medical comorbidities precluding surgery
• Parkinsonism not responsive to levodopa (suggests atypical parkinsonism)
• Advanced age is relative (no strict cutoff, but benefits diminish > 70-75 years)

Landmark Evidence:

• EARLYSTIM Trial (2013): DBS superior to best medical therapy in patients with early motor complications (mean disease duration 7.5 years); better quality of life at 2 years. [7]

Adverse Effects/Complications:

• Surgical: Hemorrhage (1-2%), infection (3-5%), lead malposition
• Stimulation-related: Dysarthria, paresthesias, mood changes, weight gain
• Hardware: Lead fracture, battery replacement (3-5 years for non-rechargeable)

What DBS Does NOT Improve:

• Cognitive symptoms (may worsen verbal fluency)
• Axial symptoms (gait freezing, postural instability) — often less responsive
• Non-motor symptoms
• "Off" symptoms that do not respond to levodopa

Levodopa-Carbidopa Intestinal Gel (LCIG/Duodopa)

Mechanism: Continuous intestinal infusion of levodopa gel via PEG-J tube directly into jejunum, bypassing variable gastric emptying.

Subcutaneous Apomorphine

Mechanism: Potent dopamine agonist delivered continuously via subcutaneous infusion.

Non-Motor Symptom Management

Multidisciplinary Care

Optimal PD management requires a team approach:

Exercise and Rehabilitation

Exercise is the only intervention with possible disease-modifying effects. [11]

Recommendation: 150 minutes/week of moderate-intensity exercise; include aerobic, strength, and balance components.

---

8. Complications

Motor Complications

As discussed above, motor fluctuations and dyskinesias are major complications of long-term levodopa therapy.

Risk factors for motor complications:

• Younger age at onset
• Higher levodopa doses
• Longer disease duration
• More severe disease
• Low body weight

Falls and Fractures

• Falls occur in 60-80% of patients during the disease course
• Leading cause of morbidity; hip fractures significantly increase mortality
• Multifactorial: postural instability, freezing of gait, orthostatic hypotension, cognitive impairment
• Prevention: physiotherapy, home assessment, medication review, treatment of OH

Aspiration Pneumonia

• Leading cause of death in PD
• Due to dysphagia (oropharyngeal) and reduced cough reflex
• Regular swallowing assessments; modified diet texture; speech therapy

Parkinson's Disease Dementia

• Point prevalence ~30-40%; cumulative risk up to 80% at 20 years
• Characteristically affects executive function, attention, and visuospatial skills (differs from Alzheimer's pattern)
• Visual hallucinations are common
• Rivastigmine is the only medication with proven efficacy [16]

Parkinson's Disease Psychosis

• Hallucinations (usually visual, well-formed) and delusions
• Continuum from "benign" insight-preserved hallucinations to delusional psychosis
• Drug-related (dopaminergic medications) but also intrinsic to disease
• Management: reduce offending medications; pimavanserin; quetiapine; clozapine

Impulse Control Disorders

• Pathological gambling, hypersexuality, compulsive shopping, binge eating, punding (stereotyped repetitive behaviors), hobbyism
• Strongly associated with dopamine agonist use; also occurs with levodopa
• Screen all patients at each visit; reduce or stop agonist; behavioral therapy

---

9. Prognosis

Disease Progression

• PD is slowly progressive over 10-25+ years
• Rate of progression varies considerably between individuals
• Factors associated with faster progression: older age at onset, akinetic-rigid phenotype, early cognitive impairment, minimal tremor

Hoehn and Yahr Staging

Life Expectancy

• Modestly reduced compared to general population
• Mortality ratio ~1.5-2.0
• Primary causes of death:
  • Aspiration pneumonia (most common)
  • Falls and complications
  • Cardiovascular disease
  • Advanced dementia with complications

Predictors of Prognosis

---

10. Evidence Summary

Landmark Trials

Major Guidelines

Emerging Therapies and Future Directions

---

11. Patient Education

Key Counseling Points

1. Chronic, progressive condition — Manage expectations; focus on maintaining function and quality of life
2. Medication timing is crucial — Levodopa works best on empty stomach; timing matters as disease progresses
3. Non-motor symptoms are real — Depression, anxiety, constipation, and fatigue are part of the disease
4. Impulse control — Warn patients and families about ICDs (gambling, shopping, hypersexuality) with dopamine agonists
5. Exercise is medicine — Regular exercise may slow functional decline
6. Driving — Discuss driving safety; patients must notify relevant authorities (country-specific requirements)
7. Advanced care planning — Consider preferences for advanced therapies and end-of-life care

Driving Considerations

• Must notify driving authority (DVLA in UK; equivalent elsewhere)
• Fitness to drive depends on motor and cognitive function
• Individual assessment required
• Sleep attacks (especially with dopamine agonists) are a specific concern

Support Resources

Allied Health Programs

---

12. Examination Focus

The "Opening Statement" for a PD Case

"This patient presents with an asymmetric, 4-6 Hz resting tremor of the right hand with a pill-rolling component, associated with cogwheel rigidity and bradykinesia demonstrated by decremental finger tapping. The eye movements are normal, there are no cerebellar signs, and there is no evidence of early autonomic failure. The unilateral onset, resting tremor, and presence of bradykinesia are consistent with the clinical diagnosis of idiopathic Parkinson's disease. I would expect this patient to respond well to levodopa therapy."

Common Viva Questions and Model Answers

1. How do you distinguish Parkinson's disease from Essential Tremor?

2. What are the red flags for atypical parkinsonism?

• Early falls (PSP)
• Early severe autonomic failure (MSA)
• Supranuclear gaze palsy, especially downgaze (PSP)
• Poor levodopa response
• Symmetric onset
• Early dementia (DLB)
• Cerebellar signs (MSA-C)

3. What is the mechanism of levodopa? Levodopa is a dopamine precursor that crosses the blood-brain barrier (dopamine itself cannot). It is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) in the brain. It is combined with a peripheral decarboxylase inhibitor (carbidopa or benserazide) to prevent peripheral conversion, reducing side effects (nausea, hypotension) and increasing CNS bioavailability.

4. Why do motor complications develop with levodopa?

• Pharmacokinetic factors: Short half-life of levodopa (90 minutes) leads to pulsatile dopamine receptor stimulation
• Pharmacodynamic factors: Loss of dopamine storage capacity in remaining neurons; postsynaptic receptor changes
• Disease progression: Fewer dopaminergic neurons to buffer fluctuations in dopamine levels

5. What are the indications for DBS in Parkinson's disease?

• Motor fluctuations and/or dyskinesias not adequately controlled with optimized oral therapy
• Good response to levodopa (predictor of DBS success)
• Medically fit for surgery
• No significant dementia or uncontrolled psychiatric illness
• Typically offered earlier in the course of motor complications (EARLYSTIM evidence)

6. What are the impulse control disorders, and how do you screen for them? ICDs include pathological gambling, hypersexuality, compulsive shopping, binge eating, and punding. Screen by asking directly: "Have you noticed any changes in behavior? Any new gambling, spending money, or sexual behaviors? Any repetitive activities like organizing or collecting?" More common with dopamine agonists but can occur with any dopaminergic therapy.

Common Mistakes to Avoid

• Diagnosing PD without bradykinesia — Tremor alone is NOT Parkinson's
• Missing the eyes — Always examine vertical gaze to rule out PSP
• Forgetting medication history — Always ask about dopamine blockers (antipsychotics, metoclopramide, prochlorperazine)
• Overlooking non-motor symptoms — Mention them in your management plan ("I would also screen for depression, sleep disorders, and cognitive impairment")
• Neglecting impulse control disorder screening — Essential when dopamine agonists are prescribed
• Forgetting the whole patient — PD management is multidisciplinary; mention physiotherapy, SALT, occupational therapy, Parkinson's nurse

---

13. Summary Tables

Quick Reference: Pharmacotherapy

Quick Reference: Motor Complications Management

---

14. References

1. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. DOI: 10.1016/S0140-6736(14)61393-3. PMID: 25904358.

2. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. DOI: 10.1038/nrdp.2017.13. PMID: 28332491.

3. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. DOI: 10.3233/JPD-181474. PMID: 30584159.

4. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303. DOI: 10.1016/S0140-6736(21)00218-X. PMID: 33848468.

5. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. DOI: 10.1002/mds.26424. PMID: 26474316.

6. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248-1266. DOI: 10.1002/mds.27372. PMID: 29570866.

7. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622. DOI: 10.1056/NEJMoa1205158. PMID: 23406026.

8. Olanow CW, Stocchi F. Levodopa: A new look at an old friend. Mov Disord. 2018;33(6):859-866. DOI: 10.1002/mds.27216. PMID: 29150893.

9. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1-12. DOI: 10.1016/j.cger.2019.08.002. PMID: 31733690.

10. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19(2):170-178. DOI: 10.1016/S1474-4422(19)30287-X. PMID: 31521533.

11. Schenkman M, Moore CG, Kohrt WM, et al. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018;75(2):219-226. DOI: 10.1001/jamaneurol.2017.3517. PMID: 29228079.

12. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. PMID: 12498954.

13. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180-198. DOI: 10.1002/mds.27602. PMID: 30653247.

14. Ba F, Martin WRW. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015;21(2):87-94. DOI: 10.1016/j.parkreldis.2014.11.007. PMID: 25487729.

15. National Institute for Health and Care Excellence. Parkinson's disease in adults: diagnosis and management. [NG71]. NICE, 2017 (updated 2023). Available at: https://www.nice.org.uk/guidance/ng71.

16. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518. DOI: 10.1056/NEJMoa041470. PMID: 15590953.

17. Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508. DOI: 10.1056/NEJMoa033447. PMID: 15590952.

18. Olanow CW, Rascol O, Hauser R, et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278. DOI: 10.1056/NEJMoa0809335. PMID: 19776408.

19. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548-560. DOI: 10.1001/jama.2019.22360. PMID: 32044947.

20. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205. DOI: 10.1016/S0140-6736(14)60683-8. PMID: 24928805.

21. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121-127. DOI: 10.1002/mds.26016. PMID: 25370355.

22. Deuschl G, Schade-Brittinger C, Krack P, et al.; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908. DOI: 10.1056/NEJMoa060281. PMID: 16943402.

---